Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret prostate-specific antigen (PSA) test results compared to existing models.

Retinoic acid suppresses immune defenses against cancer, but a new drug KyA33 boosts vaccine success and slows tumor growth ...

Increased use of organoids in cancer research: The Würzburg lighthouse project "Preclinical Models" is working towards this ...

A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a hidden link between two core features of cancer. Scientists have uncovered a ...

A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

NAYA's European Hub to Accelerate Clinical Development of its Astatine-211 Targeted Alpha Therapies and Multispecific ...

A study that was published in recent weeks has given the world a sobering view of the number of cancer diagnoses that are ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

NEW YORK, Jan. 12, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announced today that its 2026 funding opportunities are officially open for applications.